NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage developer of broad-spectrum antivirals, has announced promising results for its lead drug candidate, NV-387, in the treatment of Measles. The drug demonstrated a significant increase in survival rates in a lethal respiratory infection model using humanized mice, with survival times extending from 7.4 to 17 days, marking a 130% improvement. Notably, the study reported no observed toxicity and showed dose-dependent efficacy, underscoring the potential of NV-387 as a safe and effective treatment option.
The mechanism of NV-387 involves mimicking human cell features to bind and neutralize viruses, targeting over 90% of human pathogens. This breakthrough comes at a critical time, as global Measles cases are surging and vaccine coverage is declining, creating an urgent need for therapeutic interventions. Anil R. Diwan, PhD, highlighted the significance of these findings, stating, ‘NV-387 is on its way to become the very first drug to treat Measles.’
NanoViricides is focused on advancing NV-387 into Phase II human clinical trials, with the drug also being considered for the treatment of RSV, COVID-19, Long COVID, influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. The company’s innovative approach to antiviral therapy, leveraging host-mimetic nanomedicine, positions it as a pioneer in addressing some of the most pressing viral threats today.
For more information on the study and NanoViricides’ efforts to combat viral infections, visit https://ibn.fm/0nUwO.
This news story relied on content distributed by None. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is NanoViricides Announces Promising Results for Measles Treatment in Humanized Animal Study.
